hackint0sh/New-Dataset huggingface dataset:
Due to the destruction of gastric glands (including parietal and chief cells) in AAG patients, there is a deficiency in intrinsic factor, gastric acid, and a decrease in pepsinogen I (PG-I) levels. Insufficient gastric acid secretion leads to a compensatory increase in gastrin secretion by G cells in the gastric antrum, which acts on receptors present in enterochromaffin-like cells (ECL) in the gastric body and fundus, promoting ECL cell proliferation. Prolonged stimulation by hypergastrinemia can result in the development of ECL cell tumors, namely type 1 g-NETs. Considering the close association between type 1 g-NETs and AAG, primarily related to hypergastrinemia resulting from reduced gastric acid secretion, it is hypothesized that supplementation with gastric acid could provide negative feedback regulation of gastrin, reducing the risk of type 1 g-NET development in AAG patients. This study aims to investigate the impact of oral apple cider vinegar on gastrin levels in AAG patients, thus exploring a simple and cost-effective method to reduce the risk of type 1 g-NETs in AAG patients. conditions: Autoimmune Gastritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: oral administration of a compound digestive enzyme capsule name: oral administration of apple cider vinegar name: oral administration of both the compound digestive enzyme capsule and apple cider vinegar measure: serum gastrin levels measure: serum gastrin levels measure: the adverse reaction rates sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-01-30 uploadDate: 2024-02-15T10:32 filename: Prot_SAP_000.pdf size: 152941 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-01-30 uploadDate: 2024-02-15T10:32 filename: ICF_001.pdf size: 156619 hasResults: False
nctId: NCT06272487 id: ALN-AGT01-007 briefTitle: Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) acronym: KARDIA-3 overallStatus: RECRUITING date: 2024-02-29 date: 2025-03-20 date: 2025-12-19 date: 2024-02-22 date: 2024-04-18 name: Alnylam Pharmaceuticals class: INDUSTRY briefSummary: The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications. conditions: High Cardiovascular Risk conditions: Hypertension studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 390 type: ESTIMATED name: Zilebesiran name: Placebo measure: Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP) measure: Change from Baseline at Month 3 in 24-Hour Mean SBP Assessed by Ambulatory Blood Pressure Monitoring (ABPM) measure: Change from Baseline at Month 6 in Mean Seated Office SBP measure: Change from Baseline at Month 6 in 24-Hour Mean SBP Assessed by ABPM measure: Proportion of Patients with Mean Seated Office SBP <140 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6 measure: Proportion of Patients with 24-hour Mean SBP assessed by ABPM <130 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6 measure: Change from Baseline at Month 3 and Month 6 in Daytime and Nighttime Mean SBP and Diastolic Blood Pressure (DBP) assessed by ABPM measure: Change from Baseline at Month 3 and Month 6 in Mean Seated Office DBP measure: Change from Baseline at Month 3 and Month 6 in 24-hour Mean DBP Assessed by ABPM measure: Change from Baseline Over Time in Serum Angiotensinogen (AGT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Trial Site status: RECRUITING city: Flint state: Michigan zip: 48504 country: United States lat: 43.01253 lon: -83.68746 hasResults: False
nctId: NCT06272474 id: 0266-07/2021 - 18/07/2021 briefTitle: Virtual Reproduction of Mandibular Movement for Assessing Occlusal Interferences and Adjustments overallStatus: COMPLETED date: 2022-09-11 date: 2023-12-09 date: 2023-12-09 date: 2024-02-22 date: 2024-02-22 name: Hams Hamed Abdelrahman class: OTHER briefSummary: Computer-aided designs have considered dynamic occlusion with virtual articulator systems. However, the process involved is currently lengthy. The simplified transfer of casts from a mechanical to a virtual articulator has required bulky and expensive instruments. Recently, new methods based on mandibular motion tracking using optical devices have been introduced for integrating individual functional movement into occlusal morphology.
Materials and methods: Intraoral optical impression will be made for thirteen selected patients with endodontically treated maxillary first premolars after abutment preparation followed by buccal and lateral interocclusal records taking. Two zirconia crowns will be fabricated for each patient following regular digital workflow with twenty six zirconia crowns, which will be allocated according to the virtual method of adjustment of occlusal interferences into two groups (Group I: Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record (n=13) and Group II: Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal and lateral interocclusal records (n=13)). Then milling and sintering of all crowns will be performed following the manufacturer's instructions. The occlusion of all crowns will be analyzed using an electronic pressure analyzer. All data will be statistically analyzed and discussed in light of the results obtained. conditions: Dental Occlusion studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Single group is receiving the two interventional arms primaryPurpose: DIAGNOSTIC masking: NONE count: 26 type: ACTUAL name: CAD-CAM zirconia crowns using buccal interocclusal record. name: CAD-CAM zirconia crowns using lateral interocclusal records. measure: Static occlusal interference measure: Dynamic occlusal interference sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Alexandria Faculty of Dentistry city: Alexandria country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06272461 id: UTEM ELKI briefTitle: Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery overallStatus: RECRUITING date: 2023-10-01 date: 2024-05-30 date: 2024-06-30 date: 2024-02-22 date: 2024-04-16 name: University Tunis El Manar class: OTHER briefSummary: Patients undergoing open colorectal surgery were randomly divided into two groups: Intravenous Lidocaine (IV-Lido) vs Intravenous Ketamine (IV-Keta).
Plasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively. conditions: Colorectal (Colon or Rectal) Cancer conditions: Inflammation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intravenous Lidocaine vs intravenous ketamine primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 50 type: ESTIMATED name: Lidocaine IV name: Ketamine Injectable Solution measure: The variation of Interleukin-6 levels measure: Pain assessed by Numerical Rating Scale (NRS) measure: Post-operative nausea and vomiting measure: Bowel function. measure: Hospital length of stay. measure: Post-operative complications. sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tunisia status: RECRUITING city: Nabeul zip: 8000 country: Tunisia name: BEN ALI MECHAAL role: CONTACT phone: 53890987 phoneExt: 00216 email: mechaal_benali@yahoo.fr lat: 36.45606 lon: 10.73763 hasResults: False
nctId: NCT06272448 id: CERM2022-27 21042022 briefTitle: teleRehabilitation for pAtients With ParkInson's Disease at Any mOment acronym: RAPIDO overallStatus: RECRUITING date: 2022-11-15 date: 2024-05-31 date: 2024-05-31 date: 2024-02-22 date: 2024-02-22 name: Università Politecnica delle Marche class: OTHER name: Universita di Verona briefSummary: The goal of this clinical trial is to test the feasibility and safety of a telerehabilitation and telemonitoring approach in people with Parkinson's disease at any stage. The main questions it aims to answer are: will patients with Parkinson's disease comply with the recommended level of training at home using an ad hoc developed telerehabilitation platform? • Will this training be safe and impact the patient's well-being perception? Participants will be given a tablet and instructed to access an online platform to observe different motor tasks presented in as many video clips by experienced therapists.They will be requested to perform the motor tasks per a predetermined protocol over 3 months. Their compliance with the recommended training will be checked by physiotherapists every 15 days during phone calls, whereas their daily level of motor activity will be recorded by a smartwatch. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Before-after study with one follow-up at 3 months of treatment end primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Telerehabilitation measure: Compliance with the telerehabilitation system measure: Perceived usability of system measure: Incidence of treatment-emergent adverse events measure: User satisfaction measure: Compliance with the monitoring system measure: Feasibility of telemonitoring approach measure: Motor symptom and disability progression measure: Non motor symptom progression measure: Patients' Quality of life measure: Caregiver's burden sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Neurorehabilitation Clinic status: RECRUITING city: Ancona zip: 60126 country: Italy name: Elisa Andrenelli, Dr role: CONTACT phone: 0715965794 email: e.andrenelli@univpm.it lat: 43.5942 lon: 13.50337 facility: Università di Verona status: RECRUITING city: Verona zip: 37100 country: Italy name: Marialuisa Gandolfi, Prof role: CONTACT phone: +39 045 812 4943 email: marialuisa.gandolfi@univr.it lat: 45.4299 lon: 10.98444 hasResults: False
nctId: NCT06272422 id: 2022/0472 id: 2023-A00358-37 type: OTHER domain: IDRCB - ANSM ID briefTitle: Comparison of the Restoration of Hip Biomechanical Parameters by CT Measurement Between the 3 Surgical Techniques: RSA/Minihip/THA - Hip Replacement: 3D Planning acronym: HIP3D overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2026-03 date: 2024-02-22 date: 2024-02-22 name: University Hospital, Lille class: OTHER briefSummary: The study will analyze hip biomechanical parameters using EOS radiographic measurements pre- and post-operatively (3 months) and post-operatively (3 months) CT scans after total hip replacement (THR), neck-preserving THR of the Minihip type or hip resurfacing (HR). Clinical results will be assessed at 3 months and 1 year after surgery.
- Post-operative check-up, questionnaire and clinical examination conditions: Coxarthrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 165 type: ESTIMATED name: hip arthroplasty measure: Comparing the restoration of femoral hip offset between hip resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty. measure: Compare the anatomical restoration of frontal and axial parameters between the 3 types of intervention (PTH, Minihip and RSA). measure: Compare clinical outcomes and patient satisfaction between the 3 procedures (PTH, Minihip and RSA). measure: Correlate restoration of hip femoral offset and patient functional outcome at 3 months. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06272409 id: DEP114-III-0123 briefTitle: Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children. acronym: SIERRA overallStatus: NOT_YET_RECRUITING date: 2025-02-15 date: 2025-03-15 date: 2027-04-15 date: 2024-02-22 date: 2024-02-22 name: EMS class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years. conditions: Allergic Rhinitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 318 type: ESTIMATED name: DEP114 name: Desloratadine 0.5 MG/ML measure: To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment. measure: To evaluate the effectiveness of DEP114 in relieving nasal symptoms of moderate to severe persistent allergic rhinitis in children, throughout the treatment. measure: Evaluate the efficacy of DEP114 to relieve nasal obstruction present in moderate to severe persistent allergic rhinitis in children through the treatment. measure: Evaluate the efficacy of DEP114 to relieve coryza present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment. measure: Evaluate the efficacy of DEP114 to relieve nasal itching present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment. measure: Evaluate the efficacy of DEP114 to relieve sneezing present in persistent allergic rhinitis moderate to severe in children, three and five days after the start of treatment. measure: Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the perception of the person responsible for the participant. measure: Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the investigator's perception. sex: ALL minimumAge: 6 Years maximumAge: 11 Years stdAges: CHILD hasResults: False
nctId: NCT06272396 id: CHUBX 2023/64 briefTitle: Feasibility and Diagnostic Relevance of Recording an ECG Trace With a Connected Watch acronym: ECG-MC overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2027-03-20 date: 2028-03-20 date: 2024-02-22 date: 2024-02-22 name: University Hospital, Bordeaux class: OTHER briefSummary: Over the past few years, various systems have been developed to record ECG traces on an ambulatory basis. The latest connected watch models feature 2-electrode ECG recording. This single or six derivations can be used to derive a wealth of information about the heart's rhythm. The information that can be derived from an ECG recording with a derivation goes far beyond̀ simple differentiation between atrial fibrillation and sinus rhythm. In contrast, in various clinical situations, a tracing restricted to an ICD may prove falsely normal, wrongly reassuring a patient and delaying management. The primary objective of the study is to evaluate the sensitivity of ECG-1D or 6D recordings from a connected watch in measuring electrical parameters, compared with a standard ECG-12D, also to obtain a bank of tracings, to create and validate an artificial intelligence algorithm for the automatic analysis of ECG tracings recorded with a connected watch and also to validate the feasibility and sensitivity of recording an ECG tracing with a connected watch in children. conditions: Arrhythmias, Cardiac studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 3000 type: ESTIMATED name: Smart watch measure: Comparison of electrical parameters measured using the 2 ECG methods: P-wave amplitude measure: Comparison of electrical parameters measured using the 2 ECG methods: P-wave duration measure: Comparison of electrical parameters measured using the 2 ECG methods: QRS amplitude measure: Comparison of electrical parameters measured using the 2 ECG methods: QRS duration measure: Comparison of electrical parameters measured using the 2 ECG methods: QT/QTc measure: Creation of bank of anormal ECG trace measure: Compare the diagnostic capabilities of an ECG trace recorded with a watch against the reference method, the 12-lead ECG measure: Validate the feasibility of recording and sending of ECG tracings with a connected watch at the patient's home measure: Validate the feasibility of recording an ECG trace with a connected watch for a child measure: Validate the sensibility of an ECG trace with a connected watch for a child sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Haut-Lévèque city: Pessac zip: 33604 country: France name: Pierre BORDACHAR role: CONTACT lat: 44.81011 lon: -0.64129 hasResults: False
nctId: NCT06272383 id: HS26166 (B2023:092) briefTitle: Croup Dosing Study overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-02-22 date: 2024-02-22 name: University of Manitoba class: OTHER briefSummary: Croup is a common childhood respiratory disease that often leads to frequent emergency department visits. It is a viral infection that causes cough, throat, and airway swelling, making breathing difficult. Dexamethasone is a medication that helps to reduce swelling, making breathing easier for children. A standard dose of 0.6mg/kg is used in children. However, a lower amount (due to side effects of steroids in children) has been suggested. We will examine whether 25% less than the standard dose is equally effective in treating croup. Investigators will conduct a clinical study with the support of patients with lived experience (which, in this case, are the parents of the children) to better care for children with croup. If proven, this study can improve the outcome in children with croup. conditions: Croup studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is an internal double-blinded vanguard randomized controlled trial (RCT), which will be conducted at the Winnipeg Children's Hospital (WCH). Computerized randomization will be performed by a statistician at the George and Fay Yee Centre for HealthCare Innovation to generate the randomization list. Investigators will perform a computerized randomization stratified by age. Investigators will do a block randomization with random blocks of undisclosed block sizes over the seasons to ensure temporal distribution of croup cases is captured. Investigators will randomly assign patients to either the intervention or control in ratio 1:1. While croup is common between 6 months and 5 years, a typical croup affects children between 6 months and 3 years. Based on this, we will randomize such that this age category (6 months-3years) has almost similar distribution in each arm. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: 0.15 mg/kg dexamethasone measure: Return visits or readmissions to the hospital measure: Adverse events sex: ALL minimumAge: 6 Months maximumAge: 5 Years stdAges: CHILD hasResults: False
nctId: NCT06272370 id: PLACER-2021C3-24737-IC briefTitle: Individualizing Treatment for Asthma in Primary Care acronym: iTREAT-PC overallStatus: RECRUITING date: 2024-02-01 date: 2024-06-30 date: 2024-09-30 date: 2024-02-22 date: 2024-02-22 name: DARTNet Institute class: OTHER_GOV name: Penn State University name: Icahn School of Medicine at Mount Sinai name: University of Colorado, Denver name: RAND name: University of Washington name: Rutgers University name: University of North Carolina name: Brigham and Women's Hospital name: Reliant Medical Group name: Kelsey Research Foundation name: Wake Forest University Health Sciences briefSummary: This is a patient level randomized trial for teenagers and adults with asthma who will be randomized to four arms - enhance usual care, rescue inhaled corticosteroids, azithromycin and both rescue inhaled corticosteroids and azithromycin. Participants in all arms will be offered access to an online asthma symptom monitoring system. conditions: Asthma conditions: Bronchial Diseases conditions: Respiratory Tract Infections conditions: Lung Diseases, Obstructive conditions: Lung Diseases conditions: Respiratory Hypersensitivity conditions: Immune System Diseases studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: patient randomized trial of three different drug combinations primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 125 type: ESTIMATED name: Asthma Symptom Monitoring online tools name: Inhaled Steroids name: Azithromycin Pill measure: The annualized rate of major asthma exacerbations (a hospitalization for asthma or 72+ hours of oral/parenteral steroids). measure: Asthma control as measured by the Asthma Control Test measure: Asthma Quality of Life as measured by the Juniper Mini Asthma Quality of Life Questionnaire measure: Days Per Year Lost from Work or School/Days Unable to Carry Out Usual Activities Due to Asthma. sex: ALL minimumAge: 12 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: DARTNet Insitute status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Brian K Manning, MPH role: CONTACT phone: 800-434-0278 phoneExt: 82 email: brian.manning@dartnet.info name: Joel Shields, MA role: CONTACT phone: 80004340278 phoneExt: 84 email: joel.shields@dartnet.info name: Michelle Hernandez, MD role: PRINCIPAL_INVESTIGATOR name: Kari Stephens, PhD role: PRINCIPAL_INVESTIGATOR name: John Valenta, PhD role: PRINCIPAL_INVESTIGATOR name: Juan Wisniveski, MD role: PRINCIPAL_INVESTIGATOR name: Lipika Samal, MD role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06272357 id: Antiarrhythmic drugs briefTitle: The Use of Antiarrhythmic Drugs in Pediatrics overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2025-03-31 date: 2024-02-22 date: 2024-02-22 name: Assiut University class: OTHER briefSummary: A study on the use of antiarrhythmic drugs in pediatric age group, in Assiut University Children's Hospital, a clinical audit conditions: Antiarrhythmic Drug Adverse Reaction studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 158 type: ESTIMATED name: Antiarrhythmic drugs measure: Detect the rate of use of antiarrhythmic drugs in pediatrics and the different indications for them other than the control of arrhythmia. sex: ALL minimumAge: 30 Days maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False